Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study of Milnacipran for the Treatment of Fibromyalgia

ClinicalTrials.gov ID: NCT00314249

Public ClinicalTrials.gov record NCT00314249. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 24, 2026, 2:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III Pivotal, Multicenter, Double-blind, Randomized, Placebo-Controlled Monotherapy Study of Milnacipran for the Treatment of Fibromyalgia.

Study identification

NCT ID
NCT00314249
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Forest Laboratories
Industry
Enrollment
1,025 participants

Conditions and interventions

Conditions

Interventions

  • Placebo Drug
  • Milnacipran 100mg Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2006
Primary completion
May 31, 2008
Completion
Not listed
Last update posted
Jan 19, 2010

Started 2006

United States locations

U.S. sites
24
U.S. states
15
U.S. cities
23
Facility City State ZIP Site status
Forest Investigative Site Tuscaloosa Alabama 35406
Forest Investigative Site Fresno California 93710
Forest Investigative Site Pismo Beach California 93449
Forest Investigative Site Vista California 92083
Forest Investigative Site St. Petersburg Florida 33702
Forest Investigative Site St. Petersburg Florida 33709
Forest Investigative Site Stuart Florida 34996
Forest Investigative Site Atlanta Georgia 30328
Forest Investigative Site Springfield Massachusetts 01107
Forest Investigative Site Worcester Massachusetts 01610
Forest Investigative Site Omaha Nebraska 68134
Forest Investigative Site Haddon Heights New Jersey 08035
Forest Investigative Site Johnson City New York 13790
Forest Investigative Site Syracuse New York 13210
Forest Investigative Site Greensboro North Carolina 27408
Forest Investigative Site Cleveland Ohio 44122
Forest Investigative Site Columbus Ohio 43212
Forest Investigative Site Toledo Ohio 43623
Forest Investigative Site Eugene Oregon 97401
Forest Investigative Site Mechanicsburg Pennsylvania 17055
Forest Investigative Site Anderson South Carolina 29621
Forest Investigative Site Greer South Carolina 29651
Forest Investigative Site Richardson Texas 75080
Forest Investigative Site Virginia Beach Virginia 23454

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00314249, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 19, 2010 · Synced Jul 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00314249 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →